Table 2.

The representation of clinical trial studies of some natural compounds against BC.

Natural Compound	Nature	NCT No.	Number of Participants	Disease Type	Dose/Concentration	Duration of Trial	Trial Phase	Study Location	Reference
Curcumin	Polyphenol	NCT01740323	30	BC	8 g	8 weeks	Phase II	USA	www.clinicaltrials.gov (accessed on 27 April 2022)
Resveratrol	Stilbenoid	---	39	Metastatic BC	5 or 50 mg	3 months	Phase I	USA	[157,158]
Berberine	Alkaloids	NCT03281096	1000	Invasive BC, colorectal	300 mg	4 weeks	Phase II and III	China	www.clinicaltrials.gov (accessed on 27 April 2022)
Curcumin (iv) + Paclitaxel	Polyphenol	NCT03072992	75	Metastatic BC	300 mg	12 weeks	Phase II	Armenia	www.clinicaltrials.gov (accessed on 27 April 2022)
Quercetin	Carotenoids	---	42	Advanced BC	200 mg	2 weeks	Randomized crossover clinical trial	UK	[159,160]
Resveratrol	Stilbenoid	NCT04266353	50	TNBC	150 mg	2–4 weeks	Suspended (due to COVID-19)	California	www.clinicaltrials.gov (accessed on 27 April 2022)
Curcumin	Polyphenol	NCT01975363	30	BC (obese women)	100 mg	3 months	Pilot trial	USA	www.clinicaltrials.gov (accessed on 27 April 2022)
Genistein	Isoflavon	NCT00099008	30	BC	10 or 20 mg	84 Days	Completed	US	www.clinicaltrials.gov (accessed on 27 April 2022)